Companies › Solve Therapeutics
4 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SLV-324 | – | Phase 1 | Metastatic Solid Tumors | May 2027 |
| SLV-154 | – | Phase 1 | Advanced Cancer | Aug 2027 |
| SLR-108 Antibody-radionuclide conjugate for PET imaging | – | Phase 1 | Metastatic Solid Tumors | Jan 2028 |
| SLX-1411 Non-radiolabeled antibody | – | Phase 1 | Metastatic Solid Tumors | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07108114 | SLV-324 | Phase 1 | Metastatic Solid Tumors | Oncology | May 2027 |
| NCT06771219 | SLV-154 | Phase 1 | Advanced Cancer | Oncology | Aug 2027 |
| NCT07728942 | SLR-108 | Phase 1 | Metastatic Solid Tumors | Oncology | Jan 2028 |
| NCT07728942 | SLX-1411 | Phase 1 | Metastatic Solid Tumors | Oncology | Jan 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.